All News
Can Mycophenolate be Stopped in Stable SLE?
In patients with clinically stable systemic lupus erythematosus (SLE) and lupus nephritis, the withdrawal of mycophenolate mofetil was not significantly inferior to mycophenolate maintenance, but MMF withdrawal had numerically more reactivations, while MMF maintenance had more infections.
Read Article
COVIDs Extended Risk for Rheumatic Disease
d
EurekAlert!
Annals of Internal Medicine reports a large, binational study finding SARS-CoV-2 infection was associated with an increased risk for autoimmune inflammatory rheumatic diseases (AIRDs) that extends up to 12 months after infe
Read Article
Head to Toe, There’s No Place These Cells Won’t Go
Biana Modilevsky, DO presents her poster at RWCS 2024.
https://t.co/AEd0gk6THj https://t.co/3Rsv07WwA9
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional multicenter study of 500 ax-SpA pts on biologics found 25% w/ Irritable Bowel Syndrome (IBS) that was linked to being Female gender, unemployed, higher BASDAI & BASFI, multiple biologics, FM , anxiety, depression & lower physical activity. https://t.co/RSKVcXZwLt https://t.co/RGsw3fHr3H
Dr. John Cush RheumNow ( View Tweet)
An assessment of screening for latent tuberculosis in patients initiating b/tsDMARD therapy found over 1 in 3 new b/tsDMARD users did not receive TB screening within recommended time window, as well as variation in screening between drug classes
In AC&R
https://t.co/MGsWNZCiPW https://t.co/QRFq1lqWt6
Links:
ACR_Journals ACR_Journals ( View Tweet)
It's a whole new world regarding job/residency/fellowship INTERVIEWs - Whats your interview preference?
Dr. John Cush RheumNow ( View Tweet)
Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity
#1 (24%) w/ RP-ILD & high mortality
#2 (14%) dermatomyositis, intermediate prognosis
#3 (62%) arthritis & mechanics hands, good prognosis https://t.co/y9LMCfMIgN https://t.co/y0MbYlbbrV
Dr. John Cush RheumNow ( View Tweet)
Many with PsA Fail to Achieve Minimal Disease Activity
Despite the availability of numerous advanced therapies for PsA, there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study
https://t.co/OUb3bKo98v https://t.co/FDCBcdyIBm
Dr. John Cush RheumNow ( View Tweet)
Polyarteritis Nodosa (PAN): Clinical Features and Outcomes
A multinational study of PAN through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).
https://t.co/jNNATtKTxA https://t.co/j5o6qTL2zM
Dr. John Cush RheumNow ( View Tweet)
Australian study shows self-reported difficulties w/ ambulation (limited<=1 km) had a higher risk of hip and spinal fractures (32% to 219% more)/ Included 239 000 adults >45 yrs https://t.co/5rIkDOK69u https://t.co/iJ8o0dlGlS
Dr. John Cush RheumNow ( View Tweet)
Neonatal Fc receptor mAb (lowers Igs) development:
2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis
2023 FDA approved rozanolixizumab (Rystiggo) for MG
2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG
INTERESTING? https://t.co/HB1fJet3Bo https://t.co/OBrd2Y3nye
Dr. John Cush RheumNow ( View Tweet)
Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease
The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open.
https://t.co/hMlKxIDvlb https://t.co/eNEMuH4Tdc
Dr. John Cush RheumNow ( View Tweet)
Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/GBTh7UGn1O https://t.co/jlwVAbdIIF
Dr. John Cush RheumNow ( View Tweet)
EGPA: Benralizumab (BEN) or Mepolizumab (MEP)
A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA.
https://t.co/V0qWQ5nOzc https://t.co/SoOid5HKcV
Dr. John Cush RheumNow ( View Tweet)
Behçet’s Syndrome
A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches.
https://t.co/Yb3R4K9Zwf https://t.co/JAxqZ3FcQz
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/Kg7Dqr54dg https://t.co/X25SKggJzN
Dr. John Cush RheumNow ( View Tweet)
When Meningitis Strikes Twice
Amanda Moyer, MD, presents her poster at RWCS 2024.
https://t.co/hO8VkcqCkb https://t.co/9tfKI7dEs9
Dr. John Cush RheumNow ( View Tweet)
CD19 CAR T-Cell Therapy in Autoimmune Disease
The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious.
https://t.co/D53xeBdgsu https://t.co/dkrJ2CiSTl
Dr. John Cush RheumNow ( View Tweet)
Fever of Unknown Origin: Not Always an Infection
Roel Sanchez Baez, MD presents his poster at RWCS 2024.
https://t.co/WiDfcNHuNv https://t.co/gTs78QmE2A
Dr. John Cush RheumNow ( View Tweet)
Excess Cardiovascular Risk in Gout
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
https://t.co/ThDbAkI0VN https://t.co/uYz9Swu6sR
Dr. John Cush RheumNow ( View Tweet)